Alcon

This article is about a pharmaceutical company. For the Spanish beach volleyball player see Ester Alcon , for the Argentine actor see Alfredo Alcón .

Alcon AG
legal form	Corporation
ISIN	CH0432492467
founding	1945
Seat	Friborg , Switzerland
management	David Endicott ( CEO ) Mike Ball ( Chairman of the Board )
Number of employees	25,494 (2013)
sales	$ 7.4 billion (2019)
Branch	Pharma
Website	www.alcon.com

Alcon is a pharmaceutical company based in Freiburg (Switzerland) and operational headquarters in Fort Worth , Texas and Geneva . It specializes in ophthalmology .

history

Alcon was founded in Fort Worth , Texas , USA in 1945 by the pharmacists Robert Alexander and William Conner, from whom the name is derived. These placed an emphasis on ophthalmology from an early age.

The company was taken over by Nestlé in 1977 , who thus entered the pharmaceutical business. In 2002 Nestlé decided to bring Alcon back onto the stock exchange as a spin-off . Alcon's shares were then listed on the New York Stock Exchange . After 24.8% of Novartis was sold in December 2008, Nestlé still held 52% of the shares in Alcon and in 2010 also sold it to Novartis. Novartis paid a total of $ 38.7 billion to Nestlé for their 77% stake in Alcon.

In 2007, Alcon employed around 14,500 people in 75 countries and had sales of US $ 5.6 billion.

On January 19, 2010, Alcon announced the purchase of three ophthalmic products from Sirion Therapeutics : The two FDA-approved preparations Durezol ^® ( difluprednate ) and Zirgan ^® ( ganciclovir ) as well as the global marketing rights (except Latin America) for Zyclorin ^® ( Cyclosporin A ), which was in clinical development at the time.

In January 2010, Novartis announced the acquisition of a further 52% of the share capital and the intention to also acquire the 23% minority stake. After the complete takeover by Novartis, Alcon was merged with Ciba Vision and since then, together with some ophthalmic pharmaceuticals, has formed a new ophthalmic division within the Novartis Group.

On June 29, 2018, Novartis announced that it would spin off Alcon and bring it to the SIX Swiss Exchange and the New York Stock Exchange . The IPO finally took place on April 9, 2019. On the following day, Alcon was included in the Swiss Market Index (SMI).

Web links

Commons : Alcon  - collection of images, videos and audio files

• Alcon website
• Entry of Alcon, Inc. in the commercial register of the Canton of Zug

Individual evidence

1. ↑ Overview of employees at Novartis , accessed December 20, 2014.
2. ↑ Alcon: Annual Report 2019. Accessed on May 23, 2020 (English). 
3. ↑ Novartis subsidiary Alcon brings more jobs to Switzerland . In: Tages-Anzeiger . November 9, 2018, ISSN  1422-9994 ( tagesanzeiger.ch [accessed April 11, 2019]).
4. ↑ Completion of the sale of Alcon shares to Novartis
5. ↑ ra / cf: Alcon purchases two Sirion ophthalmic products. (No longer available online.) In: Handelszeitung . January 19, 2010, archived from the original on May 18, 2016 ; accessed on May 18, 2016 . 
6. ↑ Novartis, press release: Novartis acquires majority stake in Alcon, a global leader in ophthalmology, and proposes a merger for the full acquisition of Alcon , January 4, 2010.
7. ↑ Alcon at Novartis.ch ( Memento from July 22, 2011 in the Internet Archive )
8. ^ New Alcon Information. Accessed April 11, 2019 . 
9. ↑ Marcel Speiser: Face to face with Alcon. In: handelszeitung.ch . April 8, 2019, accessed April 9, 2019 . 
10. ↑ n-tv NEWS: Novartis subsidiary starts as heavyweight. Retrieved April 11, 2019 .